Evogene Ltd. (EVGN)
EVGN Stock Price Chart
Explore Evogene Ltd. interactive price chart. Choose custom timeframes to analyze EVGN price movements and trends.
EVGN Company Profile
Discover essential business fundamentals and corporate details for Evogene Ltd. (EVGN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
15 Oct 2010
Employees
117.00
Website
https://www.evogene.comCEO
Ofer Haviv
Description
Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small molecules, and genetic components. The company's operations are structured into three primary divisions: Agriculture, Human Health, and Industrial Applications. Within the Agriculture division, Evogene works on seed traits, agricultural chemicals, and biological products aimed at improving plant yields, with efforts spanning critical crops like corn, soybean, wheat, rice, and cotton. The Industrial Applications segment focuses on enhancing castor bean seeds for use as a raw material in various industrial applications. Meanwhile, the Human Health segment is dedicated to uncovering and developing human microbiome-based treatments for conditions including immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. Beyond these core areas, Evogene also delivers medical cannabis products. The company maintains a global presence, conducting operations in the United States, Israel, Brazil, and other international markets. It has forged key partnerships and licensing agreements with leading agricultural enterprises, such as BASF SE, Corteva, and Bayer. Additionally, its subsidiary, Canonic Ltd., collaborates with Cannbit Ltd. on the development of innovative medical cannabis offerings. Established in 1999, Evogene Ltd. is based in Rehovot, Israel.
EVGN Financial Timeline
Browse a chronological timeline of Evogene Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 26 Aug 2026
EPS estimate is -$0.27, while revenue estimate is $325.00k.
Earnings released on 20 May 2026
EPS came in at -$0.60 falling short of the estimated -$0.27 by -122.22%, while revenue for the quarter reached $334.00k , missing expectations by -4.57%.
Earnings released on 5 Mar 2026
EPS came in at -$0.61 falling short of the estimated -$0.26 by -134.62%, while revenue for the quarter reached $314.00k , beating expectations by +14.18%.
Earnings released on 20 Nov 2025
EPS came in at -$0.31 falling short of the estimated -$0.26 by -19.23%, while revenue for the quarter reached $312.00k , beating expectations by +13.45%.
Earnings released on 28 Aug 2025
EPS came in at -$1.06 , while revenue for the quarter reached $884.00k .
Earnings released on 21 May 2025
EPS came in at -$0.38 surpassing the estimated -$0.63 by +39.20%, while revenue for the quarter reached $2.44m , beating expectations by +25.82%.
Earnings released on 6 Mar 2025
EPS came in at $0.06 surpassing the estimated -$0.72 by +108.33%, while revenue for the quarter reached $1.61m , missing expectations by -67.78%.
Earnings released on 21 Nov 2024
EPS came in at -$1.31 falling short of the estimated -$1.01 by -29.70%, while revenue for the quarter reached $1.74m , missing expectations by -52.00%.
Earnings released on 22 Aug 2024
EPS came in at -$1.06 falling short of the estimated -$0.12 by -783.33%, while revenue for the quarter reached $605.00k , missing expectations by -24.38%.
Stock split effective on 25 Jul 2024
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 23 May 2024
EPS came in at -$0.80 falling short of the estimated -$0.09 by -788.89%, while revenue for the quarter reached $4.19m , beating expectations by +19.71%.
Earnings released on 7 Mar 2024
EPS came in at -$1.30 surpassing the estimated -$1.40 by +7.14%, while revenue for the quarter reached $578.00k , missing expectations by -83.49%.
Earnings released on 15 Nov 2023
EPS came in at -$0.80 surpassing the estimated -$1.70 by +52.94%, while revenue for the quarter reached $3.77m , beating expectations by +313.96%.
Earnings released on 17 Aug 2023
EPS came in at -$1.70 surpassing the estimated -$1.90 by +10.53%, while revenue for the quarter reached $654.00k , missing expectations by -37.12%.
Earnings released on 18 May 2023
EPS came in at -$1.50 surpassing the estimated -$1.60 by +6.25%, while revenue for the quarter reached $641.00k , missing expectations by -27.16%.
Earnings released on 9 Mar 2023
EPS came in at -$0.70 surpassing the estimated -$2.10 by +66.67%, while revenue for the quarter reached $660.00k , beating expectations by +4.76%.
Earnings released on 17 Nov 2022
EPS came in at -$1.60 surpassing the estimated -$2.00 by +20.00%, while revenue for the quarter reached $466.00k , beating expectations by +98.58%.
Earnings released on 31 Aug 2022
EPS came in at -$2.10 falling short of the estimated -$1.80 by -16.67%, while revenue for the quarter reached $312.00k , beating expectations by +35.26%.
Earnings released on 26 May 2022
EPS came in at -$2.00 falling short of the estimated -$1.40 by -42.86%, while revenue for the quarter reached $237.00k , missing expectations by -23.30%.
Earnings released on 10 Mar 2022
EPS came in at -$1.80 surpassing the estimated -$2.00 by +10.00%, while revenue for the quarter reached $311.00k , beating expectations by +68.72%.
Earnings released on 17 Nov 2021
EPS came in at -$1.90 falling short of the estimated -$1.70 by -11.76%, while revenue for the quarter reached $151.00k , missing expectations by -44.07%.
Earnings released on 11 Aug 2021
EPS came in at -$1.50 falling short of the estimated -$0.18 by -733.33%, while revenue for the quarter reached $135.00k , missing expectations by -55.00%.
EVGN Stock Performance
Access detailed EVGN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
